Skip to content

Korsana Biosciences

US · KRSA #2830 by market cap Listed 1970
37.56 +2.11 +5.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Revenue annual, last 2 years

Income statement

Line item 2024 2025
Revenue ----
Gross profit ----
Selling & admin expenses 53.00K4.51M
Research & development 56.00K32.79M
Operating profit -109.00K-37.29M
Pretax profit -88.00K-35.64M
Tax ----
Net profit -88.00K-35.64M
Basic EPS 0-7
Diluted EPS -0.02-7.07

Balance sheet

Line item 2024 2025
Total current assets 10.11M154.60M
Cash & ST investments 10.11M154.14M
Inventory ----
Total assets 10.11M154.60M
Total current liabilities 78.00K12.49M
Short-term debt ----
Long-term debt ----
Total liabilities 10,042,000.00188,564,000.00
Total equity 66.00K-33.97M
Retained earnings -88.00K-35.73M

Cash flow

Line item 2024 2025
Operating cash flow 44.00K-22.41M
Depreciation & amortization ----
Free cash flow 44.00K-22.41M
Dividends paid ----
Stock buybacks / issuance ----
Ending cash balance 10.11M154.14M

Returns & efficiency

Line item 2024 2025
ROE % -133.33--
ROA % -0.87-43.28
ROIC % -165.15--
5-year avg ROE % ----
EBIT margin % ----
FCF / sales % ----
Current ratio 129.5912.38
Quick ratio 129.5912.34
Debt / assets ----
LT debt / equity ----
Interest coverage ----
Revenue CAGR (3Y) % ----
Net income CAGR (3Y) % ----
FCF CAGR (3Y) % ----

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Korsana Biosciences discussion 0 comments

Add a comment